Company / Profit Margin
Inhibikase Therapeutics, Inc. Profit Margin History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-7304.7%
FY2024
5-year range
-14625.9% / -407.7%
FY2021-FY2024
Trend
+50.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin returned to growth in FY2024 after 2 years of decline, reaching -7304.7%.
Based on SEC 10-K filings.
-7304.7% in FY2024 with a 3-year CAGR of -6897.0%.
Declined from -476.9% to -7304.7% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -6897.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, profit margin increased 50.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -7304.7% | +50.1% |
| FY2023 | -14625.9% | -2967.0% |
| FY2022 | -476.9% | -17.0% |
| FY2021 | -407.7% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026